The Food and Drug Administration (FDA) reports that a new supply of Zosyn (piperacillin and tazobactam; Pfizer) Injection 2.25g, 3.375g, and 4.5g is expected to be available in June 2015.

The initial shortage of Zosyn Injection, reported in April 2014, was due to a delay in shipping of the drug. Other generic manufacturers are currently reporting an intermittent backorder and/or a limited supply of certain dosage strengths.

RELATED: Resistance to Common Antimicrobials Increasing

Zosyn is a broad-spectrum penicillin + β-lactamase inhibitor indicated for the treatment of susceptible intra-abdominal infections (eg, appendicitis, peritonitis), skin and skin structure, moderate community-acquired pneumonia, moderate to severe nosocomial pneumonia, postpartum endometritis, and pelvic inflammatory disease.

For more information visit